Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced clinical trial approval from China’s National Medical Products Administration (NMPA) for KHN922, a novel dual-payload antibody-drug conjugate (ADC) targeting HER3 for advanced solid tumor treatment. The independently developed candidate by Kanghong Biologics features a unique dual-payload mechanism inhibiting tumor cells at both RNA and DNA levels while overcoming drug resistance via P-gp and HSP70 downregulation.
Clinical relevance – efficacy in human tumor heterogeneity
Strategic Context & Competitive Position
Factor
Implication
HER3 ADC Landscape
Patritumab deruxtecan (Daiichi/U-Canbrella) leading; HER3-DXd establishes HER3 as viable ADC target; KHN922 seeks differentiation via dual-payload
Dual-Payload Innovation
First-in-class approach – simultaneous RNA/DNA attack may address payload resistance and tumor heterogeneity vs. single-payload competitors
Anti-Resistance Mechanism
P-gp/HSP70 modulation – unique among HER3 ADCs; potential for combination with chemotherapy and resistance reversal in refractory patients
Kanghong Biotech Pivot
Category 1 biologic approval validates Kanghong Biologics innovation subsidiary; ADC platform emerging as core capability beyond traditional ophthalmology franchise
Development Strategy
China-first Phase I → global partnership potential with differentiated dual-payload data package
Clinical Timeline: Phase I Q2 2026 initiation; dose-escalation in HER3-expressing solid tumors (NSCLC, breast, gastric); preliminary efficacy 2027
Commercial Potential: Peak China sales RMB 300–500 million; global licensing opportunity $200+ million given novel dual-payload IP and anti-resistance profile
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase I safety, dual-payload pharmacokinetics, and clinical efficacy for KHN922. Actual results may differ due to manufacturing complexity of dual-payload ADCs, competitive dynamics with established HER3-targeted therapies, and regulatory requirements for novel payload combinations.-Fineline Info & Tech
By Fineline Cube